Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness

Journal of Infectious Diseases

Volumn 195, Issue 3, 2007, Pages 322-329

  Bisser, Sylvie ^a,b   N'Siesi, François Xavier ^c,e   Lejon, Veerle ^a   Preux, Pierre Marie ^b   Van Nieuwenhove, Simon ^d   Bilenge, Constantin Miaka Mia ^e   Büscher, Philippe ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITÉ DE LIMOGES   (France)

^c Centre de Développement Intégral

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Programme National de Lutte contre la Trypanosomiase Humaine Africaine   (Democratic Republic Congo)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; MEBENDAZOLE; MELARSOPROL; NIFURTIMOX;

ABDOMINAL PAIN; ADULT; AFRICAN TRYPANOSOMIASIS; AGGRESSION; ANOREXIA; ARTHRALGIA; ARTICLE; BRAIN DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEATH; DELIRIUM; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; EPIGASTRIC PAIN; FATIGUE; FEMALE; FEVER; FOOT PAIN; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HYPOTENSION; INCREASED APPETITE; LOW DRUG DOSE; MALE; MEMORY DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; TREMOR; TRYPANOSOMA; URTICARIA; VOMITING;

EID: 33846407934     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510534     Document Type: Article

References (31)

1. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355:1419-25.
2. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 2004; 364:789-90.
3. Van Nieuwenhove S, Schechter PJ, Declercq J, Bone G, Burke J, Sjoerdsma A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alfa-difluoromethyl ornithine) an inhibitor of ornithine decarboxylase: first field trial. Trans R Soc Trop Med Hyg 1985; 79:692-8.
4. Van Nieuwenhove S. Present strategies in the treatment of human African trypanosomiasis. In: Dumas M, Bouteille B, Buguet A, eds. Progress in human African trypanosomiasis, sleeping sickness. Paris: Springer, 1999:253-81.
5. Wang CC. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 1995; 35:93-127.
6. Fairlamb AH. Future prospects for the chemotherapy of human trypanosomiasis. I. Novel approaches to the chemotherapy of trypanosomiasis. Trans R Soc Trop Med Hyg 1990; 84:613-7.
7. Janssens PG, De Muynck A. Clinical trials with "nifurtimox" in African tryanosomiasis. Ann Soc Belg Méd Trop 1977; 57:475-9.
8. Moens F, De Wilde M, Ngato K. Essai de traitement au nifurtimox de la trypanosomiase humaine africaine. Ann Soc Belg Méd Trop 1984; 64:37-43.
9. Van Nieuwenhove S. Advances in sleeping sickness therapy. Ann Soc Belg Méd Trop 1992; 72:39-51.
10. Pépin J, Milord F, Mpia B, et al. An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg 1989; 83:514-7.
11. Pépin J, Milord F, Meurice F, Ethier L, Loko L, Mpia B. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Trans R Soc Trop Med Hyg 1992; 86:254-6.
12. Legros D, Evans S, Maiso F, Enyaru JCK, Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999; 93:439-42.
13. Stanghellini A, Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 2001; 6:330-4.
14. Legros D, Ollivier G, Gastellu-Etchegorry M, et al. Treatment of human African trypanosomiasis-present situation and needs for research and development. Lancet Infect Dis 2002; 2:437-40.
15. Matovu E, Enyaru JCK, Legros D, Schmid C, Seebeck T, Kaminsky R. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop Med Int Health 2001; 6:407-11.
16. Jennings FW. Future prospects for the chemotherapy of human trypanosomiasis. II. Combination chemotherapy and African trypanosomiasis. Trans R Soc Trop Med Hyg 1990; 84:618-21.
17. Mpia B, Pépin J. Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. Trop Med Int Health 2002; 7:775-9.
18. Legros D, Fournier C, Gastellu Etchegorry M, Maiso F, Szumilin E. Echecs thérapeutiques du melarsoprol parmi des patients traités au stade tardif de trypanosomose humaine africaine à T. b. gambiense en Ouganda. Bull Soc Pathol Exot 1999; 92:171-2.
19. Van Nieuwenhove S, Betu-Ku-Mesu VK, Diabakana PM, Dedercq J, Bilenge CM. Sleeping sickness resurgence in the DRC: the past decade. Trop Med Int Health 2001; 6:335-41.
20. Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. b.gambiense trypanosomiasis. Ann Soc Belg Méd Trop 1978; 58:169-76.
21. Lejon V, Büscher P, Sema NH, Magnus E, Van Meirvenne N. Human African trypanosomiasis: a latex agglutination field test for quantifying IgM in cerebrospinal fluid. Bull World Health Organ 1998; 76:553-8.
22. Meulemans O. Determination of total protein in spinal fluid with sulfosalicylic acid and trichloroacetic acid. Clin Chim Acta 1960; 5:757-61.
23. Cattand P, Miézan BT, de Raadt P. Human African trypanosomiasis: use of double centrifugation of cerebrospinal fluid to detect trypanosomes. Bull World Health Organ 1988; 66:83-6.
24. World Health Organization (WHO). Control and surveillance of African trypanosomiasis. WHO Tech Rep Ser 1998; 881:1-113.
25. Schmid C, Richer M, Bilengue MMC, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 2005; 191:1922-31.
26. Doua F, Miézan TW, Sanon SR, Boa YF, Baltz T. The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am J Trop Med Hyg 1996; 55:586-8.
27. Pépin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994; 33:1-47.
28. Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 2001; 6:390-400.
29. Teasdale G, Jennet B. Assessment of coma and impaired consciousness: a practical scale. Lancet 1974; 2:81-4.
30. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky performance status scale: an examination of its reliability and validity in a research setting. Cancer 1984; 53:2002-7.
31. Lejon V, Legros D, Rosengren L, Gastellu-Etchegorry M, Büscher P. Biological data and clinical symptoms as predictors of astrogliosis and neurodegeneration in second stage Trypanosoma brucei gambiense sleeping sickness patients. Am J Trop Med Hyg 2001; 65:931-5.